Share Prices & Company Research

Market News

19 Jan 2021 | 15:24

ValiRx adds four new patents to portfolio in 2020

(Sharecast News) - Clinical-stage drug development company ValiRx updated the market on its patent portfolio on Tuesday, reporting that it continued to build in 2020 with four patents granted during the last 12 months. The AIM-traded firm said that in addition, this month the European Patent Office notified it of its intention to grant a patent which would extend patent cover for VAL201 into metastatic cancer.

It explained that those statements of protection were similar to those granted by the US patent office announced in November 2019, and would create a "broad coverage of use" of the peptide in an important area of oncology.

"It is important for ValiRx to continue to build value in our product portfolio by protecting intellectual property," said chief executive officer Dr Suzy Dilly.

"The patenting process involves rigorous scrutiny of the proposal, testing for novelty and utility before a patent is allowed to be granted.

"Granted patents provide protection of the intellectual value of our research and provide further evidence to potential partners of the value of our products."

Dr Dilly said she was "very pleased" that the company had continued to extend protection across its three core products through 2020 and into January of the new year.

"This is an important component of value creation in the company and a high priority for the board."

At 1409 GMT, shares in ValiRx were down 2.39% at 26.6p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.